Reports from McLean Hospital Highlight Recent Findings in Alzheimer Disease (Plasma Amyloid Beta X-42/x-40 Ratio and Cognitive Decline In Suspected Early and Preclinical Alzheimer's Disease).

Předmět:	ALZHEIMER'S disease COGNITION disorders AMYLOID CENTRAL nervous system diseases MILD cognitive impairment BLOOD diseases
Zdroj:	Hematology Week; 2024, p384-384, 1p
Abstrakt:	A recent report from McLean Hospital in Belmont, Massachusetts highlights the use of blood-based biomarkers for diagnosing early and preclinical stages of Alzheimer's disease. The study focused on the plasma amyloid beta X-42/X-40 ratio and its correlation with cognitive decline. The researchers found a significant correlation between the plasma and cerebrospinal fluid levels of amyloid beta X-42/X-40, suggesting that assessing this ratio could be a promising biomarker for early or preclinical Alzheimer's disease. The study was supported by the Federal Ministry of Education & Research. [Extracted from the article]
Databáze:	Complementary Index
Externí odkaz:	Zobrazit plný text záznamu